Skip to content

â??To study the effectiveness of Ivermectin with standard of care treatment versus standard of care treatment for COVID 19 cases. A Pilot Study

â??To study the effectiveness of Ivermectin with standard of care treatment versus standard of care treatment for COVID 19 cases. A Pilot Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/04/024858
Enrollment
50
Registered
2020-04-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B338- Other specified viral diseases

Interventions

Intervention1: Ivermectin: Cases of COVID 19 shall be treated with Ivermectin 200 to 400mcg per kg body weight on day 1 and day 2 along with standard treatment of the hospital protocol Control Interve

Sponsors

Max Super Speciality Hospital A Unit of Devki Devi Foundation
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects within age group between 18 to 75 years 2. With either sex, male or female 3. Confirmed case of COVID-19 at Max Hospitals.

Exclusion criteria

Exclusion criteria: Patients who are critically sick

Design outcomes

Primary

MeasureTime frame
This study aims to confirm the antivirus effectiveness of Ivermectin on coronavirus i.e COVID 19 then to explore its potential use in the combating to the COVID 19 pandemics.Timepoint: Viral load will be monitored at 1, 3 & 5 days from beginning of trial drug (48 hours interval) Until the report comes negative. Drug will be delivered on daily basis upto eradication of virus or completion of the trial

Secondary

MeasureTime frame
Safety of the drug vs standard care of treatment will be checkedTimepoint: Treatment will be provided until the eradication of virus or completion of the trial.

Countries

India

Contacts

Public ContactRajesh Saxena

Internal Medicine, Max Super Speciality Hospital (DDF), Saket

docmishra@yahoo.co.in9810193145

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026